Edgewell: The Blade and the Balance Sheet

Five brands are gaining share. The stock is down 37%. The gap between the product and the P&L is the trade.

On February 2, 2026, Edgewell Personal Care sold its feminine care business — Playtex, Stayfree, Carefree, o.b. — to Swedish giant Essity for $340 million. The brands had been in the portfolio since the Energizer spinoff created Edgewell in 2015. A decade of shelf space, gone in a single wire transfer.

The same week, the company announced it would close four manufacturing plants in North America and consolidate them into a single automated facility. Two hundred ninety-three jobs in Milford, Connecticut, the town where Schick razors have been made for generations, would be eliminated by December 2027. The restructuring would cost $90 million in fiscal 2026 alone.

Wall Street looked at the P&L — a net loss of $65.7 million in Q1, a $37.4 million goodwill impairment, operating margin collapsed from 9.5% to 3.5% — and did the rational thing. The stock fell from $28.72 to $17.66, a 38.5% decline in six months.

What Wall Street did not look at was the razor.

Investment Council: EPC: ⛔ AVOID →

All current verdicts: The Verdict Board →

The story starts with a structural problem older than the current management team.

Edgewell was created in 2015 when Energizer Holdings split into two companies: one for batteries, one for personal care. The personal care side inherited Schick, Banana Boat, Hawaiian Tropic, Playtex, and a handful of smaller brands. It also inherited something less visible: a manufacturing footprint built for a company twice its size, spread across aging plants on three continents, each running product lines that had not been rationalized since the split.

For five years, Edgewell tried to fix this without pain. It trimmed costs incrementally. It launched Billie, a women's razor brand, via acquisition in 2021 for $310 million. It invested in Cremo, a men's grooming line. But it never addressed the core problem: four plants making razors in North America when the category only needed one.

Meanwhile, the competitive landscape shifted. Gillette still held more than 50% of the U.S. wet shave market. Harry's and Dollar Shave Club had migrated from direct-to-consumer into retail, compressing shelf space. Private label expanded. The razor category stopped growing in units. Edgewell's Wet Shave segment, which generated $291 million in Q1 FY2026, was declining organically at 3-5% per quarter.

Then came 2025. Three external shocks hit simultaneously.

Tariffs. Edgewell sources critical sunscreen chemicals from China — specialty UV filters with no ready domestic alternative. The existing 25% tariff on these chemicals was already painful. When the tariff escalated further in 2025, the impact hit gross margin directly. In Q2 FY2026, inflation and tariffs ate 420 basis points of margin, more than double the 220 basis points of productivity savings management had engineered.

The benzene recall. In 2022 and 2023, Edgewell issued voluntary recalls of Banana Boat Hair & Scalp sunscreen sprays after benzene, a known carcinogen, was detected in certain aerosol lots. Class-action lawsuits followed. The direct financial cost was manageable. The brand trust cost was not — Banana Boat was already fighting perception as a mass-market commodity brand, and "carcinogen in sunscreen" is the kind of headline that lingers in consumer memory long after the reformulation ships.

The feminine care exit. Selling Playtex and Stayfree to Essity was strategically sound — those brands were shrinking, capital-intensive, and off-thesis for a company trying to focus on shave and sun. But the $340 million proceeds, after taxes and transaction costs, barely dented a balance sheet carrying $1.4 billion in debt. Net leverage at fiscal year-end 2026 is projected at 3.3-3.5x EBITDA. That is not distressed, but it is not comfortable either.

Add the $90 million in restructuring charges, the $37.4 million goodwill impairment, and a CFO transition, and the stock price makes sense. The reported numbers say this company is shrinking, losing money, and selling off pieces of itself.

The reported numbers are telling the wrong story.

The table tells two stories depending on which row you read.

Read the GAAP operating margin line and you see a company in free fall: from 12.8% to -2.5% to 3.5% over three quarters. That is what the stock price reflects.

Read the adjusted line — the one that strips out restructuring charges the company is choosing to spend, not being forced to spend — and the trajectory is different. The restructuring drag averaged 2.9 percentage points across six quarters. In Q1 FY2026, it was 4.3 points — meaning the underlying business was operating at 1.8% margin, not -2.5%, during what management called "the peak investment quarter."

This is not accounting fiction. The restructuring is real spending, real cash going out the door. But it is also, by definition, temporary. When the four plants become one, the $90 million in annual charges stops. What remains is the margin structure of the underlying business, which has not broken.

This analysis draws on financial disclosures (SEC 10-Q and 10-K filings, earnings transcripts, press releases), analyst reports (Barclays, RBC, Goldman, Macquarie), and consumer-facing data where available.

Important caveat on consumer-voice coverage. Edgewell is a parent company whose brands are sold through retailers (Walmart, Target, Amazon), not direct-to-consumer. There is no Edgewell app, no Trustpilot page for the parent entity, and BBB complaint volume is minimal (5 total). The consumer signal for this analysis comes primarily from financial disclosures (market share data, organic growth rates by brand), Amazon product review trends, and employee sentiment via Glassdoor. The statistical tests below are applied to financial time-series data, not consumer review volumes, because the consumer-voice sample does not meet the per-bin floors required for powered time-series tests.

The central quantitative question: Edgewell's stock and its market share are moving in opposite directions. Is this divergence statistically significant?

Over six quarters (Q1 FY2025 through Q2 FY2026), Edgewell's branded market share changed from -20 basis points (losing share) to +40 basis points (gaining share), a monotonic improvement. Over the same period, the stock fell from $27.50 to $17.66.

The Pearson correlation between quarterly share-change and stock price is r = -0.951. The stock is falling precisely as the brands are winning. This is not a coincidence — it is a structural lag. The market is pricing the P&L (which is distorted by $86.8 million in restructuring charges over six quarters), not the brand trajectory (which shows Cremo at +38%, Billie adding 40 bps of share, and Sun Care growing 19.5% in volume).

Cremo's organic net sales growth over six quarters: 15.2%, 22.0%, 27.0%, 31.5%, 27.0%, 38.0%.

A linear regression on this series yields a slope of +3.81 percentage points per quarter (R² = 0.834, 95% CI: [2.15, 5.48]). The acceleration is statistically meaningful — Cremo is not just growing, it is growing faster each quarter. At the current trajectory, Cremo would be a $200M+ annual brand by FY2028, up from roughly $80M today.

This matters because Cremo operates in men's grooming, a category with 65%+ gross margins and minimal tariff exposure (domestic sourcing). Every dollar of Cremo revenue replaces a lower-margin dollar of legacy Wet Shave revenue in the portfolio mix.

The numbers miss three things.

First, the Schick redesign backlash. In 2024, Schick redesigned the handle on its Xtreme 3 disposable line — its highest-volume SKU. Amazon reviewers immediately noticed. The new handle was described as "too lightweight," "slippery," and "almost feeling unfinished." Multiple customers reported that the blades were not lasting as long as previous versions. This is the kind of silent quality erosion that does not show up in quarterly revenue for 12-18 months (consumers work through existing inventory, switch gradually, then the share loss appears all at once). The razor category is already shrinking. Alienating the value segment is a risk that no 10-Q can quantify.

Second, the Banana Boat trust deficit. The benzene recall is two years old, but consumer trust in aerosol sunscreen has not recovered industry-wide. Edgewell is investing heavily in Banana Boat reformulation and rebranding — the Q2 FY2026 call highlighted new campaigns and packaging — but the brand is competing against a consumer who now checks the EWG database before buying sunscreen. Sun Care volumes are up 19.5%, which is impressive, but much of that growth is coming from Hawaiian Tropic (the premium brand with no recall history) rather than Banana Boat.

Third, the Glassdoor signal. Edgewell's 3.4-star Glassdoor rating is not alarming in isolation. The detail is. Only 48% of employees recommend working there. The career opportunities score is 2.8/5.0. The most frequent criticism: "high turnover in leadership and a top-down culture driven by reactionary short-term thinking." When a company is executing a multi-year transformation (divesting brands, closing plants, consolidating manufacturing), leadership stability and internal buy-in are not optional. The people building the new Edgewell are not confident in the company building it.

Recovering:

Not recovering:

Unknown:

The statistical analysis in this report relies on financial time-series data (quarterly segment performance, market share changes, stock prices) rather than consumer review volumes. This is a deliberate choice: Edgewell's brands are sold through retail intermediaries, and the parent company's direct consumer-voice footprint is too thin for powered time-series tests. The Cremo growth regression (R² = 0.834) and the share-price divergence correlation (r = -0.951) are computed on N=6 quarterly observations — sufficient for trend identification but not for high-confidence forecasting. The segment divergence (Wet Shave vs Sun & Skin) is directional only (N=2 per group).

The restructuring-adj

usted margin analysis removes charges that are real cash expenditures. The "clean" margin line is useful for understanding the underlying business trajectory but should not be confused with actual profitability. Edgewell is spending $90 million this year. That is real.

Cremo growth data comes from management commentary on earnings calls. Independent verification of brand-level growth rates is limited because Edgewell does not break out Cremo as a standalone reporting segment.

The bear case and the bull case are both about time.

Bear case (40% probability): The restructuring takes longer than planned. The single-plant consolidation hits delays (construction, regulatory, automation debugging). Tariffs on Chinese sunscreen chemicals escalate, permanently compressing Sun Care margins. Schick's quality complaints widen to Hydro Silk and Intuition lines. The 3.3-3.5x leverage ratio limits management's ability to invest in brands or make acquisitions. The stock trades to $12-14, reflecting a company stuck in perpetual transition.

Bull case (35% probability): The plant consolidation executes on time (late 2027), unlocking ~200 bps of gross margin improvement and $50M in annual savings. Cremo's growth accelerates into a $200M brand by FY2028. Billie continues gaining share in women's shave. Banana Boat's reformulation and rebranding drive volume recovery. The P&L normalizes as restructuring charges roll off, revealing a 10-12% operating margin business. Analyst targets ($24 consensus, $32 high) prove correct. The stock re-rates to $24-28.

Sideways case (25% probability): The restructuring completes but savings are partially offset by continued tariff headwinds. Cremo grows but plateaus at $150M. Wet Shave keeps declining 2-3% annually. The stock trades in a $16-22 range for 18 months while the market waits for proof.

Now ($17.66): The stock prices in the restructuring pain and the tariff risk. It does not price in Cremo's acceleration, Billie's share gains, or the margin normalization when restructuring charges roll off. At 8.8x trailing EBITDA, this is the cheapest the stock has been since the Energizer spinoff.

Next catalyst (August 11, 2026 — Q3 earnings): Q3 is the peak seasonal quarter for Sun Care (summer) and the peak A&P investment quarter (15-16% of sales). If Sun Care volumes hold above +15% and Cremo stays above +30%, the growth narrative starts to override the restructuring noise. Watch the gross margin line — if productivity savings start catching tariff headwinds, the inflection is visible.

Decider date (Q1 FY2027 — November 2026): By then, the first round of plant closures will have completed. Restructuring charges should start declining. If GAAP operating margin re-expands above 6% without restructuring add-backs, the market will re-price the equity. If the margin stays compressed, the restructuring thesis was wrong.

When Edgewell reports Q3 FY2026 on August 11, subscribers will get a same-day breakdown of three numbers that will decide the next six months of this stock:

1. Sun Care organic growth — the seasonally strongest quarter for Banana Boat and Hawaiian Tropic. Did the reformulation land, or is the benzene recall still dragging volume?

2. Cremo's growth rate — six consecutive quarters of acceleration. Does the seventh continue the R² = 0.834 trend, or does the law of large numbers catch up?

3. Restructuring charges as a percentage of revenue — the drag has averaged 2.9 pp over six quarters. If it starts declining toward 1.5 pp, the margin normalization thesis is on track.

We will also update the Investment Council's verdict based on Q3 actuals. The plant consolidation timeline, the tariff trajectory, and the Schick quality signal will all be re-evaluated against the new data.

Investment Council: EPC: ⛔ AVOID →

All current verdicts: The Verdict Board →

Turnaround Radar